Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alkermes, Amicus, Antengene, Arcturus, Astrazeneca, Autobahn, Avidity, Canbridge, Epygenix, Galmed, Hummingbird, Iaso, Mustang, Protalix, Regeneron, Shenzhen Kangtai Biological, Sorrento, Vaxart.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Realview Imaging.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alzamend, Ardelyx, BMS, Erytech, GSK, I-Mab, Imago, Janssen, Junshi, Revolo.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Exini Diagnostics, Nuvasive.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Alzamend, Arrowhead, Basilea, Dicerna, Everest, Fusion, Genentech, Eli Lilly, Nuvox, Oncopeptides, Scancell, Transcenta, Viatris, Vico.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biofourmis, Cepheid, Fluxergy, Nanovibronix.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abeona, Apic, Arcturus, I-Mab, Lexeo, Mycovia, Nrx, Pharmamar, Takeda, Xoma.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Asensus Surgical, Medtronic, Promega, Synchron, Voxneuro.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Betterlife, Day One, Hope, Kineta, Kronos, Lyndra, Merck, Petros, Sol-Gel, Ultragenyx.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Ascentage, Ascletis, Astellas, Astrazeneca, Biovaxys Technology, Direct Biologics, Gtreebnt, Humanigen, Kyowa Kirin, Levena, Mabpharm, Moderna, Oblato, Organicell Regenerative Medicine, Rarestone, Regeneron, Sanofi, Sinovac, Sorrento, Swedish Orphan Biovitrum, Yisheng.